Tolerability, safety, and efficacy of ziprasidone (80-160 mg/d) versus olanzapine (10-20 mg/d), risperidone (4-8 mg/d) or quetiapine (300-750 mg/d) in pretreated patients with schizophrenia, schizoaffective disorder or schizophreniform disorders - a 12-week open-label, multicenter clinical trial
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Ziprasidone (Primary) ; Olanzapine; Quetiapine; Risperidone
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Sponsors Pfizer; Viatris
- 29 Oct 2005 New trial record.